Published 29-05-2026
Keywords
- Pancreatic cancer,
- MicroRNA-4486,
- Serum biomarker,
- Cell proliferation
Copyright (c) 2026 Cambridge Science Advance
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Abstract
Objective: To investigate the expression characteristics and clinical diagnostic value of microRNA-4486 (miR-4486) in the serum of patients with pancreatic cancer, as well as its impact on the biological behavior of pancreatic cancer cells. Methods: A total of 40 patients diagnosed with pancreatic cancer from January 2018 to December 2024 were selected as the case group, and 40 healthy individuals during the same period were included as the control group. Real-time quantitative PCR (q RT-PCR) was used to detect the expression level of serum miR-4486. The human pancreatic cancer cell line PANC-1 was cultured in vitro and transfected with miR-4486 mimics and inhibitors, respectively. Cell proliferation, migration, and invasion capabilities were assessed using CCK-8 and Transwell assays. Results: The expression level of serum miR-4486 in patients with pancreatic cancer was significantly higher than that in the healthy control group (P < 0.05). High expression of serum miR-4486 was significantly associated with tumor size ≥ 3 cm, TNM stages III-IV, and lymph node metastasis (all P < 0.05). In vitro functional experiments showed that overexpression of miR-4486 promoted the proliferation, migration, and invasion of PANC-1 cells, whereas its inhibition significantly suppressed these phenotypes (all P < 0.05). Conclusion: miR-4486 is highly expressed in the serum of patients with pancreatic cancer and is closely related to tumor progression. It can regulate the proliferation, migration, and invasion of pancreatic cancer cells. These findings suggest that miR-4486 may serve as a potential diagnostic biomarker and therapeutic target for pancreatic cancer.
References
- Li G, Bai Y, A Y. Research progress of gene testing in systemic treatment of pancreatic cancer[J]. Chinese Journal of Clinical Research, 2024, 37(9): 1432-1437.
- Zheng J, Amat M, Guo L, et al. Mechanism of circ-MTHFD1L in promoting the progression of pancreatic ductal adenocarcinoma[J]. Journal of Hepato-pancreato-biliary Surgery, 2022, 34(4): 217-226.
- Zhang M, Liu X, Mai H, et al. Expression and clinical significance of SLC7A11 in KRAS-mutated pancreatic cancer[J]. The Journal of Practical Medicine, 2022, 38(24): 3125-3128.
- Zhao D, Huang J, Zhang Y, et al. Mechanism study of MicroRNA-105-5p/PPM1A on proliferation, migration and invasion of pancreatic cancer PANC-1 cells[J]. China Journal of Modern Medicine, 2024, 34(15): 41-51.
- LI Y, BAI Y, et al. Identification of circulating serum miRNAs as novel biomarkers in pancreatic cancer using a penalized algorithm[J]. Oncol Lett, 2021, 22(6): 858. DOI: 10.3892/ol.2021.13118.
- PALMIERI V, MONTELEONE F, et al. Unveiling the microRNA landscape in pancreatic ductal adenocarcinoma patients and cancer cell models[J]. BMC Cancer, 2024, 24: 1307. DOI: 10.1186/s12885-024-13070-5.
- ZHOU C, CHEN L, et al. miR-4486 enhances cisplatin sensitivity of gastric cancer cells by restraining the JAK3/STAT3 signalling pathway[J]. J Chemother, 2022, 34(1): 35-44. DOI: 10.1080/1120009X.2021.1896839.
- WANG W, CHEN L, et al. miR-4486 reverses cisplatin-resistance of colon cancer cells via targeting ATG7 to inhibiting autophagy[J]. Exp Ther Med, 2021, 22(6): 1465. DOI: 10.3892/etm.2021.10899.
- ALI S, ALMHANNA K, et al. Emerging roles of miRNAs in the development of pancreatic cancer[J]. Biomed Pharmacother, 2021, 141: 111914. DOI: 10.1016/j.biopha.2021.111914.